Compare AKRO & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AKRO | TSLX |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 2.2B |
| IPO Year | 2019 | 2014 |
| Metric | AKRO | TSLX |
|---|---|---|
| Price | $54.65 | $22.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $73.56 | $23.50 |
| AVG Volume (30 Days) | ★ 2.4M | 404.1K |
| Earning Date | 11-07-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 9.07% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.04 |
| Revenue | N/A | ★ $464,512,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.07 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.34 | $18.58 |
| 52 Week High | $58.40 | $25.17 |
| Indicator | AKRO | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 68.63 | 61.87 |
| Support Level | $54.30 | $22.51 |
| Resistance Level | $54.70 | $22.84 |
| Average True Range (ATR) | 0.17 | 0.32 |
| MACD | -0.10 | 0.14 |
| Stochastic Oscillator | 71.07 | 87.36 |
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.